1. Introduction & Learning Objectives (MCQ Below )

Welcome and Session Overview

Opioid dependence remains a complex, chronic, and highly stigmatised condition that affects not only individuals but also families, healthcare systems, and wider communities. In recent years, long-acting injectable treatments have emerged as an important option within opioid substitution therapy, offering new ways to support stability, adherence, and shared care.

Buvidal® (prolonged-release buprenorphine injection) represents a shift away from daily supervised dosing towards a more flexible, patient-centred approach. While its clinical benefits are increasingly supported by evidence, misconceptions, unrealistic expectations, and poor communication can undermine its effectiveness. These misunderstandings may exist among patients, families, and even healthcare professionals.

This CPD session is designed to equip healthcare professionals with the knowledge and confidence to explain Buvidal clearly and honestly, to manage expectations, and to integrate it effectively within shared-care models. Emphasis is placed not only on pharmacology and evidence, but also on communication, myth-busting, and compassionate engagement with patients and their families.

Learning Outcomes

By the end of this session, participants will be able to:

• Explain what Buvidal is and how it works, including its pharmacological profile as a prolonged-release buprenorphine formulation and how this differs from daily oral or sublingual opioid substitution therapies.

• Describe appropriate clinical use cases for Buvidal, identifying which patients may benefit most and understanding its role within a broader treatment and recovery framework rather than as a standalone solution.

• Understand and communicate the evidence base and limitations, including what current research shows about effectiveness, retention in treatment, safety, and quality-of-life outcomes, as well as where evidence is still evolving.

• Recognise common myths and misconceptions surrounding Buvidal, such as beliefs about “replacing one addiction with another” or expectations of a rapid cure, and respond to these concerns using clear, non-judgemental, evidence-based explanations.

• Support patient-centred discussions with users and families, helping to build trust, manage expectations, and encourage shared decision-making within multidisciplinary and shared-care settings.

This Training session aims to move beyond technical knowledge alone, supporting healthcare professionals to use Buvidal as part of a realistic, ethical, and compassionate approach to opioid dependence treatment.

2. What Is Buvidal?

Definition and Formulation

Buvidal® is a prolonged-release injectable formulation of buprenorphine, designed for the treatment of opioid dependence. It is administered as a subcutaneous injection, available in weekly and monthly dosing schedules, allowing flexibility based on clinical need and stage of treatment.

The active ingredient, buprenorphine, is a well-established medication used globally in opioid dependence treatment. It has been prescribed for decades in various formulations, most commonly as sublingual tablets or films. Buvidal represents a newer delivery system that maintains therapeutic buprenorphine levels over an extended period, reducing the need for daily dosing and frequent supervised consumption.

The prolonged-release formulation forms a depot at the injection site, from which buprenorphine is gradually released into the bloodstream. This controlled release is central to both its clinical benefits and the conversations clinicians must have with patients about expectations and limitations.

How Buvidal Works: Pharmacology and Mechanism of Action

Buprenorphine is a partial agonist at the μ-opioid receptor. This pharmacological property underpins its role in opioid dependence treatment:

As a partial agonist, buprenorphine activates opioid receptors sufficiently to reduce withdrawal symptoms and cravings, but not to the same extent as full opioid agonists such as heroin, morphine, or methadone.

This results in a “ceiling effect”, where increasing doses do not produce proportionally increasing opioid effects. Clinically, this lowers the risk of respiratory depression compared with full agonists, although risk is not eliminated, particularly when combined with other sedatives.

When administered as Buvidal, buprenorphine is released slowly and predictably over days or weeks, depending on whether a weekly or monthly formulation is used. This steady plasma concentration helps to:

• Minimise peaks and troughs associated with daily dosing

• Reduce withdrawal symptoms between doses

• Decrease the psychological focus on daily medication-taking

Importantly, because the medication is delivered as an injection, there is no take-home product that can be lost, diverted, or misused, which is a key consideration in certain clinical and social contexts.

Indication and Place in Treatment

Buvidal is indicated for the maintenance treatment of opioid dependence in adults. It is not a cure for addiction, nor is it intended to be used in isolation.

Its use should always be embedded within a comprehensive treatment framework, which includes:

• Medical assessment and monitoring

• Psychological support and counselling

• Social support, including housing, employment, and family engagement where appropriate

From a shared-care perspective, Buvidal can support stability by reducing the burden of daily attendance at clinics or pharmacies, while still allowing regular clinical review and multidisciplinary involvement.

Healthcare professionals should be clear that Buvidal is a maintenance therapy designed to support recovery and reduce harm. Its effectiveness depends not only on pharmacology, but also on realistic expectations, patient engagement, and coordinated care across services.

3. Clinical Use and Shared Care

Appropriate Patients

Buvidal is not intended for every person with opioid dependence. Its value lies in careful patient selection, where the formulation addresses specific clinical, social, or practical challenges that may limit the effectiveness of daily oral or sublingual opioid substitution therapy.

Buvidal may be particularly appropriate for:

• Patients who struggle with adherence to daily supervised therapy, including those who miss doses, disengage from services, or find daily attendance burdensome or destabilising.

• Individuals at risk of diversion or misuse of take-home medication, or where supervision requirements create barriers to ongoing engagement.

• Patients with difficulty attending clinics or pharmacies daily, such as those with unstable housing, employment commitments, caregiving responsibilities, physical disability, or significant anxiety related to supervised consumption environments.

• Patients who are clinically stabilised on sublingual buprenorphine and wish to transition to a longer-acting formulation for convenience, privacy, or improved quality of life.

• It is essential that patients understand that Buvidal does not remove the need for engagement with treatment services. Rather, it changes the structure of care, potentially reducing daily contact while maintaining clinical oversight and support.

Administration and Dosing

Buvidal is administered as a subcutaneous injection by a trained healthcare professional. It is available in two dosing schedules, allowing treatment to be individualised:

• Weekly formulations are commonly used during initiation and early stabilisation, particularly when assessing tolerability, response, and dose adequacy.

• Monthly formulations are typically introduced once the patient is clinically stable, providing sustained therapeutic coverage with fewer injections.

• Dosing protocols may vary depending on national guidelines, local service models, and individual patient factors. Transitioning from sublingual buprenorphine requires careful planning to avoid precipitated withdrawal and to ensure adequate symptom control.

Regular clinical review remains essential, particularly during initiation and dose changes, to monitor:

• Withdrawal symptoms and cravings

• Side effects, including injection-site reactions

• Concurrent substance use

• Mental health and social stability

Shared Care Principles

Buvidal is most effective when used within a shared-care framework, rather than as a standalone intervention. Shared care recognises opioid dependence as a long-term condition requiring coordinated input from multiple professionals.

Key components of shared care include:

• Joint management between the patients, their carers, specialist services, general practitioners, pharmacists, and allied healthcare professionals such as counsellors or social workers.

• Clear communication pathways to ensure that changes in clinical status, missed appointments, or safeguarding concerns are identified and addressed promptly.

• Ongoing monitoring of clinical stability, including side effects, co-prescribed medications, and risks related to polysubstance use.

• Active engagement with psychosocial support, recognising that medication alone does not address the psychological, behavioural, and social dimensions of dependence.

• Tailored support for families and carers, where appropriate and with patient consent, to help them understand the role of Buvidal, manage expectations, and reduce fear or misinformation.

From a patient-centred perspective, shared care should aim to promote autonomy, dignity, and continuity, while maintaining appropriate clinical safeguards. Buvidal can reduce the visibility and burden of treatment, but it does not remove the need for therapeutic relationships and ongoing support.

4. Evidence Base and Key Research Findings

Buvidal is supported by a growing body of clinical evidence examining its effectiveness, safety, and impact on patient experience. For healthcare professionals, understanding this evidence is essential—not only to guide prescribing decisions, but also to communicate realistically with patients and families, particularly where expectations may be overly optimistic or shaped by misinformation.

This section summarises key findings from the literature, including data from peer-reviewed studies such as the Addiction (Wiley) publication, and places these findings into practical clinical context.

Efficacy and Treatment Retention

Clinical trials and observational studies consistently demonstrate that prolonged-release injectable buprenorphine is comparable or non-inferior to sublingual buprenorphine in terms of treatment retention.

The Addiction journal study (Wiley) showed that patients receiving long-acting injectable buprenorphine achieved similar rates of continued engagement in treatment compared with those on daily sublingual formulations. Importantly, outcomes were not limited to retention alone but also included:

Reduction in illicit opioid use, as assessed through self-report and urinary toxicology

Stable suppression of withdrawal symptoms and cravings

Predictable plasma buprenorphine levels, avoiding daily fluctuations seen with oral dosing

These findings reinforce that Buvidal is clinically effective, but not superior in all respects for every patient. It should be framed as an alternative delivery method, not a more powerful medication.

Adherence and Service Engagement

One of the most consistently reported advantages of long-acting injectable buprenorphine is improved adherence.

Studies published in PubMed-indexed journals highlight that depot formulations:

Reduce missed doses

Lower rates of unplanned treatment interruption

Decrease the need for frequent clinic or pharmacy visits

From a service perspective, fewer visits may ease pressure on overstretched systems. From a patient perspective, reduced attendance requirements can:

Improve privacy and dignity

Support employment or caregiving responsibilities

Reduce treatment fatigue

Additionally, because Buvidal is administered as an injection with no take-home supply, diversion risk is significantly reduced. This has implications not only for individual safety, but also for public health and community trust in opioid substitution programmes.

Safety and Tolerability

Buprenorphine’s pharmacology underpins much of its safety profile. As a partial μ-opioid receptor agonist, it has a ceiling effect on respiratory depression, making overdose less likely than with full opioid agonists such as methadone or heroin.

However, it is essential to communicate clearly that:

Risk is reduced, not eliminated

Overdose risk increases significantly when buprenorphine is combined with benzodiazepines, alcohol, or other CNS depressants

Injection-site reactions can occur, though these are generally mild and self-limiting

Health professionals should avoid presenting Buvidal as “safe” in absolute terms. Instead, it should be described as safer relative to full agonists, while still requiring vigilance, monitoring, and patient education. Remember the key is harm reduction and supporting a holistic recovery. 

Patient-Centred Outcomes and Quality of Life

Beyond clinical markers, several studies have explored how long-acting injectable buprenorphine affects patient experience.

Research by Melichar et al. and others indicates that some patients report:

• Reduced anxiety related to daily dosing

• Less preoccupation with medication

• Improved sense of normality and control

• Greater satisfaction with treatment

These improvements are not universal. Some patients prefer daily contact or struggle with the perceived loss of control associated with long-acting injections. This highlights the importance of shared decision-making rather than protocol-driven prescribing.

Putting the Evidence into Perspective

When discussing evidence with patients, families, or colleagues, it is helpful to emphasise that:

Buvidal is effective, not curative

It supports stability but does not replace psychological or social interventions

Benefits depend on engagement, context, and individual preference

A practical way to frame this evidence is to compare Buvidal with other opioid substitution options:

Buvidal vs Daily Buprenorphine or Methadone

Retention: Comparable

Convenience: Higher with Buvidal

Overdose risk: Lower than full agonists; similar to sublingual buprenorphine

Diversion risk: Significantly lower with Buvidal

This balanced framing helps prevent false hope, while still acknowledging genuine advantages.

We encourage the reading of the below references 

References – Section 4: Evidence Base and Key Research Findings

Lintzeris N, Dunlop A, Haber P, et al.

Supervised injectable prolonged-release buprenorphine versus daily sublingual buprenorphine for opioid dependence: A randomised clinical trial.

Addiction. 2023.

Wiley Online Library.

DOI: 10.1111/add.16171 

Referenced for: Treatment retention,Reduction in illicit opioid use,Comparative efficacy with sublingual buprenorphine

U.S. National Library of Medicine – PubMed Emily Martin et al 2022 Journal of Substance Abuse Treatment Volume 139, August 2022, 108776

Long-acting injectable buprenorphine for opioid use disorder: clinical outcomes and adherence. 

PubMed-indexed literature.

Referenced for: Improved adherence, Reduced missed doses, Reduced clinic attendance burden, Reduced diversion risk

Healthdirect Australia

Buprenorphine – safety, overdose risk, and interactions.

Referenced for: Partial agonist ceiling effect, Reduced overdose risk compared with full agonists, Risks associated with CNS depressants (alcohol, benzodiazepines)

Melichar JK, et al.

Patient-reported outcomes with prolonged-release buprenorphine in opioid dependence.

Published in PMC / peer-reviewed journals.

Referenced for: Quality of life improvements Reduced anxiety and craving Patient satisfaction and acceptability

European Medicines Agency (EMA)

Buvidal®: Summary of Product Characteristics (SmPC).

Referenced for: Indication Safety profile Administration considerations

How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis Joanne Neale et al ADDICTION Volume118, Issue7 July 2023 Pages 1329-1339

In the next section, we will explore common myths and misconceptions surrounding Buvidal, and how healthcare professionals can address these confidently and compassionately in conversations with patients and families.

5. Myths, Misconceptions, and Communication Strategies

Misunderstandings about opioid substitution treatments are common and can significantly affect engagement, adherence, and family support. Long-acting injectable treatments such as Buvidal may attract both unrealistic expectations and undue fear, particularly when patients or families have prior experiences of addiction treatment that were negative or poorly explained.

Healthcare professionals play a critical role in reframing these narratives using clear, compassionate, and evidence-based communication.

Myth 1: “This will make me high again or replace one addiction with another.”

This is one of the most frequently expressed concerns among patients and families.

Buvidal contains buprenorphine, which is a partial μ-opioid receptor agonist. Unlike full opioid agonists, buprenorphine produces a limited opioid effect, even as the dose increases. This is known as the ceiling effect.

Key points to communicate:

Buprenorphine is designed to reduce withdrawal symptoms and cravings, not to produce euphoria.

Most patients do not experience a ‘high’ when appropriately dosed.

The prolonged-release formulation provides stable blood levels, avoiding the peaks and troughs that can reinforce addictive behaviours.

When families express concern that treatment is “replacing one drug with another,” it can be helpful to reframe Buvidal as a medical treatment for a chronic condition, similar to insulin for diabetes or inhalers for asthma.

Myth 2: “Once I’m on Buvidal, I’m cured.”

At the other end of the spectrum, some patients and families may view Buvidal as a quick or permanent solution.

It is essential to clarify that Buvidal is a maintenance treatment, not a cure. While it can significantly improve stability and reduce harm, it does not address:

• Psychological drivers of substance use

• Trauma, mental health conditions, or social stressors

• Behavioural patterns linked to addiction

• Effective communication should emphasise that:

• Recovery is a process, not an event

• Medication supports recovery but does not replace it

• Ongoing psychosocial support, goal setting, and review remain essential

Avoid framing treatment success solely in terms of abstinence. Instead, focus on improved functioning, safety, and engagement.

Myth 3: “If I miss a dose, it doesn’t really matter.”

The prolonged-release nature of Buvidal can lead some patients to underestimate the importance of follow-up and scheduled dosing.

While Buvidal provides sustained coverage, missed injections still require clinical attention. Failure to attend appointments may indicate:

• Emerging instability

• Relapse risk

• Psychosocial stressors

• Disengagement from care

Healthcare professionals should explain that:

• Missed doses require assessment and coordinated follow-up

• Dosing schedules are part of a broader safety framework

• Ongoing contact with services remains important, even if visits are less frequent

• This helps reinforce that Buvidal reduces treatment burden, but does not remove the need for care.

Communication Tips for Healthcare Professionals

Effective myth-busting depends as much on how information is delivered as on what is said.

Practical strategies include:

Use non-judgemental, person-first language (e.g. “treatment” rather than “replacement”, “person with opioid dependence” rather than labels)

Listen actively before correcting misconceptions

Acknowledge fears and past experiences without dismissing them

Involve families and carers with the patient’s consent, particularly when misinformation is driving anxiety or resistance

Be honest about limitations and uncertainties to maintain trust

Clear, respectful communication helps patients and families move from fear or false hope toward realistic, shared understanding—a cornerstone of effective shared care.

6. Case Studies & Discussion (10 mins)

Case A: Patient with Poor Clinic Adherence

Case Summary

Ahmed is a 38-year-old man with a history of opioid dependence for over 10 years. He has been receiving sublingual buprenorphine as part of a supervised treatment programme. Over the past six months, he has frequently missed pharmacy appointments and clinical reviews.

He reports that daily attendance at the clinic is difficult due to irregular employment, transport issues, and increasing anxiety around supervised consumption. Urine drug screens show intermittent illicit opioid use, though he remains engaged with services and expresses a desire to “get stable” and reduce the impact of treatment on his daily life.

Ahmed asks whether Buvidal might be “an easier option that means I don’t have to keep coming in.”

Myths vs Facts

Myth

“Buvidal means I won’t need to engage with services anymore.”

“Because it lasts a month, missing appointments won’t matter.”

“An injection will fix the problem without needing other support.”

Facts

Buvidal reduces the frequency of dosing but does not remove the need for ongoing care and review.

Missed appointments still require follow-up and assessment.

Medication can support stability, but psychosocial factors and engagement remain central to treatment success.

Appropriate Shared-Care Responses

Assess whether poor adherence is driven by practical barriers rather than lack of motivation.

Explore Buvidal as a potentially appropriate option, framing it as a way to reduce treatment burden while maintaining clinical oversight.

Involve the GP, specialist service, and pharmacist to ensure:

Clear dosing and follow-up plans

Agreed responsibilities across services

Provide clear education about:

What Buvidal can and cannot do

The importance of keeping review appointments

Consider additional psychosocial input to address anxiety, work instability, and transport challenges.

Red Flags to Monitor

Ongoing illicit opioid use despite adequate dosing

Repeated non-attendance for injections or reviews

Increasing disengagement once daily supervision is removed

Polysubstance use, particularly benzodiazepines or alcohol

Unrealistic expectations that Buvidal alone will resolve addiction

Reflection Prompt for Participants

Is Buvidal being considered to support recovery, or primarily to reduce service contact?

How would you explain the role of Buvidal to prevent false expectations?

What safeguards would you put in place before and after transition?

Case B: Family Concerned About Long-Acting Injectables

Case Summary

Fatima is a 29-year-old woman receiving treatment for opioid dependence. She has recently stabilised on sublingual buprenorphine and has expressed interest in switching to Buvidal to reduce daily medication reminders and improve privacy at work.

Her parents are strongly opposed to the idea. They believe that a long-acting injection means the drug is “stronger,” “stays in the body for too long,” and could “damage her organs” or “trap her in addiction for months.” They are particularly anxious about the idea that the medication “cannot be removed once injected.”

Fatima has given consent for her family to be involved in discussions, but feels torn between her own preferences and her parents’ fears.

Myths vs Facts

Myths

“An injection is stronger and more dangerous than tablets.”

“Once injected, nothing can be done if something goes wrong.”

“Long-acting treatment locks someone into addiction.”

Facts

Buvidal contains the same active medication (buprenorphine) as sublingual therapy; the difference is the delivery system, not drug strength.

The prolonged-release formulation provides stable blood levels, not higher peaks.

While the medication cannot be removed once administered, dosing is carefully selected, and patients are clinically monitored.

Long-acting treatment supports stability; it does not prevent recovery or future treatment changes.

Appropriate Shared-Care Responses

Acknowledge the family’s fear as understandable, particularly if past experiences of addiction have been traumatic.

Explain the pharmacology in simple, non-technical language:

Same medication

Slower release

No daily “ups and downs”

Emphasise that Buvidal is reviewed regularly, even if administered monthly.

Reinforce that the decision is patient-centred, while still valuing family involvement.

Provide written information or trusted resources for families to review in their own time.

Ensure all professionals involved (specialist, GP, counsellor) give consistent messages.

Red Flags to Monitor

Family pressure overriding the patient’s informed choice

Fear-based misinformation leading to disengagement

Patient feeling conflicted or guilty about treatment decisions

Breakdown in trust between patient, family, and care team

Lack of clarity about consent and boundaries in shared care

Reflection Prompts for Participants

How would you explain the concept of “same drug, different delivery” to a worried family?

What language would help reduce fear without minimising risk?

How do you balance family involvement with patient autonomy?

Case C: Transitioning from Sublingual Therapy

Case Summary

James is a 45-year-old man who has been receiving sublingual buprenorphine for opioid dependence for the past three years. He has remained abstinent from illicit opioids, attends appointments reliably, and is engaged with psychosocial support.

James requests to switch to Buvidal because he feels that daily medication reinforces a sense of being “still sick” and makes travel and work commitments difficult. He believes that a monthly injection will be “more stable” and expects that it may allow him to disengage from services over time.

Clinicians agree that he is clinically stable, but there are differing views within the care team about the timing of transition and the level of follow-up required.

Myths vs Facts

Myths

“If someone is stable, they no longer need regular follow-up.”

“Monthly injections mean fewer risks and less monitoring.”

“Transitioning is straightforward and always improves outcomes.”

Facts

Stability on sublingual therapy does not remove the need for ongoing clinical review, particularly during treatment changes.

Transitioning requires careful dosing and monitoring to avoid under- or over-treatment.

Long-acting formulations may improve convenience, but not all patients prefer or benefit from them.

Continued engagement supports early identification of relapse risk or emerging mental health concerns.

Appropriate Shared-Care Responses

Confirm clinical stability, including:

Current dose and adherence

Absence of ongoing illicit opioid use

Mental health and social stability

Develop a clear transition plan, agreed across specialist, GP, and pharmacy teams.

Set expectations explicitly:

Buvidal reduces daily dosing, not clinical contact

Reviews will continue, particularly in early months

Monitor response after transition:

Withdrawal symptoms or cravings

Injection-site reactions

Changes in mood or functioning

Encourage continued psychosocial support, even when medication feels less intrusive.

Red Flags to Monitor

Desire to disengage rapidly from services following transition

Minimisation of relapse risk due to perceived “stability”

Unrecognised mental health deterioration

Polysubstance use emerging once daily supervision ends

Poor communication or disagreement within the shared-care team

Discussion Prompt for Participants

What criteria would you use to decide readiness for transition?

How would you frame follow-up expectations to prevent disengagement?

How do you manage differing opinions within a multidisciplinary team?

Case D: Opioid Use in a Culturally Unacceptable Context

Case Summary

Yusuf is a 34-year-old man from a close-knit cultural and religious community in which drug use is considered deeply shameful and morally unacceptable. He has been using opioids in secret for several years and presents late to services after a non-fatal overdose.

Yusuf agrees to treatment but is fearful that engaging with opioid substitution therapy will confirm community suspicions that he is “weak,” “immoral,” or “beyond help.” His family are unaware of his drug use, and he is adamant that they must not find out. He expresses concern that taking buprenorphine — particularly as an injectable medication — would make him “no better than still using drugs.”

The care team is considering Buvidal as an option to support stability and reduce visible contact with treatment services.

Myths vs Facts

Myths

“Using medication for addiction is morally wrong.”

“Taking buprenorphine means I am still a drug user.”

“Injectable treatment is worse and more shameful than tablets.”

“My community will never accept medical treatment for addiction.”

Facts

Opioid dependence is a medical condition, not a moral failing.

Buprenorphine is a treatment, not an intoxicant when used appropriately.

Long-acting injectable therapy can reduce visibility and stigma by limiting daily clinic attendance.

Cultural and religious values often emphasise preservation of life, health, and dignity, which align with treatment goals.

Appropriate Shared-Care Responses

Approach discussions with cultural humility, avoiding assumptions or judgement.

Use language that frames treatment as:

Harm reduction

Health preservation

Responsibility rather than failure

Explore Buvidal as a way to:

Minimise public exposure

Reduce daily reminders of illness

Support discreet, structured care

Where appropriate and with consent, involve:

Trusted community figures

Faith-sensitive counselling services

Ensure confidentiality is explicitly discussed and respected.

Red Flags to Monitor

Intense shame leading to disengagement or concealment of relapse

Fear of disclosure preventing honest communication

High psychological distress or self-stigma

Isolation from support networks

Risk of abrupt disengagement to “protect honour”

Reflection Prompts for Participants

How would you frame Buvidal in a way that aligns with cultural or religious values?

What language might unintentionally increase shame or resistance?

How can services protect confidentiality while still ensuring safety?